Important MeSH terms and keywords used were: glucagon-like peptide 1 (GLP-1), GLP-1 analogue, incretin, dipeptidyl peptidase 4 (DPP-4) inhibitor, atherosclerosis, arteriosclerosis, atherogenesis, plaque, intima media thickness (IMT), flow-mediated dilation (FMD), adiponectin, leptin, endothelin, E-selectin, resistin, pentraxin, brain natriuretic peptide (BNP), monocyte chemotactic protein (MCP), vascular cell adhesion molecule-1 (VCAM-1), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP), triglyceride and cholesterol
Our synergistic formulations (Glow Blend, Klow Wolverine) combine these mechanisms with the angiogenesis of BPC-157 and the actin regulation of TB-500 for research protocols in complete skin regeneration
It is currently in late-stage clinical trials (phase 3) and has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Contact PointHealth today to schedule your personalized treatment and take the first step toward a healthier, more energized you
You know how GLP-1 meds can make your stomach feel full on a normal meal, then a simple protein shake suddenly feels like too much
